Quantcast

Latest Sirolimus Stories

2011-06-15 08:00:00

BRIDGEWATER, N.J., June 15, 2011 /PRNewswire-FirstCall/ -- Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, today announced it will no longer pursue the development of the NEVO(TM) Sirolimus-Eluting Coronary Stent in order to focus on other cardiovascular therapies where significant patient need exists.

2011-05-19 10:42:00

PARIS, May 19, 2011 /PRNewswire/ -- OrbusNeich announced that data from multiple clinical trials supporting the safety and efficacy of the Genous Stent in cases where prolonged dual antiplatelet therapy (DAPT) is not advisable were featured today during the HEALING Symposium titled "How to assess and treat patients who are not suitable candidates for prolonged dual antiplatelet therapy" at EuroPCR 2011 in Paris. Presenters discussed current treatment alternatives to drug eluting stents (DES)...

2011-05-12 08:00:00

HONG KONG, May 12, 2011 /PRNewswire/ -- OrbusNeich today announced that data from multiple studies of the Genous Stent will be presented at EuroPCR 2011 in Paris.

2011-05-11 07:00:00

DURHAM, N.C., May 11, 2011 /PRNewswire/ -- Micell Technologies, Inc.

2011-05-05 17:50:00

EAST HANOVER, N.J., May 5, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that the US Food and Drug Administration (FDA) approved Afinitor® (everolimus) tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease(4).

2011-05-02 14:47:56

A drug commonly used to treat kidney cancer may increase the effectiveness of chemotherapy for mesothelioma.

2011-04-12 13:59:00

EAST HANOVER, N.J., April 12, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of Afinitor® (everolimus) tablets for the treatment of patients with advanced neuroendocrine tumors (NET) of pancreatic origin. The recommendation was provided after presentation of data from the everolimus RADIANT (RAD001 In Advanced Neuroendocrine Tumors) trial...

2011-04-05 21:22:08

Researchers at the University of Pennsylvania School of Medicine may have found a way to turn an adaptive cellular response into a liability for cancer cells.

2011-03-23 08:00:00

HONG KONG, March 23, 2011 /PRNewswire/ -- OrbusNeich today announced that 12-month outcomes data from a subset analysis of the global e-HEALING registry were published online ahead of print in the Journal of Interventional Cardiology and demonstrated the effectiveness and safety of the company's Genous Stent in diabetic patients, with low definite and probable stent thrombosis (ST) comparable to non-diabetics. The study investigated the 1,236 diabetic patients from the e-HEALING registry,...

2011-03-21 02:00:00

HONG KONG, March 21, 2011 /PRNewswire/ -- OrbusNeich today announced that it has filed a lawsuit in the Netherlands against Dr. Pavel Cervinka and Masaryk Hospital in Usti nad Labem, Czech Republic, where Dr. Cervinka is head of the hospital's Cardiology Department.


Word of the Day
aphotic
  • Having no light.
  • Of or relating to the region of a body of water that is not reached by sunlight and in which photosynthesis is unable to occur.
The word 'aphotic' comes from Greek roots meaning 'without' and 'light'.
Related